$612 | SAVE $83 | Single User
$1228 | SAVE $167 | Global License

Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Aug 2013 | 56 | In Stock
Related Topics: FDA , GlaxoSmithKline , Healthcare , Pfizer

Introduction

Scope


Based on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later this month (it has a PDUFA date of August 17).


A once-daily integrase inhibitor, dolutegravir has been developed by ViiV Healthcare, a joint venture between GlaxoSmithKline, Pfizer and Shionogi. The drug was granted priority review by the FDA in February having been submitted for regulatory approval in December 2012.


Dolutegravir is poised to become the second available integrase inhibitor, following in the footsteps of Merck & Co.'s Isentress (raltegravir), which was approved in October 2007 and generated global sales of .5 billion in 2012.


A key advantage for dolutegravir versus Isentress is its once-daily dosing profile. This is widely expected to support uptake, following Phase III study results (from the SPRING-2 trial), which demonstrated non-inferiority for dolutegravir versus Isentress.


Potential usage of dolutegravir as a first-line therapy option has also been boosted by Phase III data (from the SINGLE study) demonstrating superiority to Gilead Sciences' gold-standard three-drug combination Atripla (when dosed in combination with abacavir and lamivudine) - see ViewPoints: Analysts hike peak forecasts for GlaxoSmithKline, Pfizer and Shionogi HIV drug.


These results triggered analysts to increase their forecasts for dolutegravir, and according to data from Bloomberg, the ViiV drug is expected to generate global sales of .1 billion by 2018. Significantly, in head-to-head trials with Atripla, Gilead's newer products Stribild and Complera had only demonstrated non-inferiority. In addition to strong efficacy, analysts have noted the potential for a better resistance profile with dolutegravir (no notable resistance in treatment naive patients versus 2-3 percent for Stribild) and fewer drug-drug interactions (due to it being a non-boosted regimen). Extension study data will provide greater clarity on these issues.


However, although dolutegravir is now positioned as a keenly anticipated market entrant there remain some question marks regarding its commercial outlook. Some analysts have noted, for example, that combination use with Epzicom (abacavir) could prove to be a barrier to uptake (given the safety profile of GlaxoSmithKline's older drug), while dolutegravir may fail to demonstrate sustained superiority versus Atripla over a longer duration of therapy (superiority versus Atripla in the SINGLE study may have also been boosted by higher drop-out rates among patients taking Gilead's drug, a number of analysts have noted).


Others have also argued that despite its status as a seemingly best-in-class integrase inhibitor, there is a chance that physicians could use dolutegravir primarily in Isentress failure patients (similarly as to how newer generation antibiotics are increasingly 'held back' to treat patients who have developed resistance to older drugs). According to consensus forecasts, Isentress sales will reach .6 billion in 2013, but stabilise at this level for the next few years.


Puchase Reasons


To help gauge a more accurate view on how dolutegravir may shape the HIV market, this week's Physician Views poll will ask US-based infectious disease specialists:


  • How aware/informed they are about dolutegravir ahead of its pending PDUFA date

  • How they expect the availability of dolutegravir to impact their usage of Gilead’s Stribild

  • What percentage of dolutegravir usage they anticipate to occur in Isentress failure patients

  • Whether combination use with Epzicom will have any negative impact on their prescribing of the drug

  • What percentage of total patients they expect to be prescribing dolutegravir to in two year's time
  • Table of Contents
    for Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market? [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    56 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 12% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
    ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
    ScopeWith the diabetes market an important therapeutic area for a host of pharmaceutical manufacture...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market? [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...